Senate Finance Committee Chair Ron Wyden (D-OR) (Francis Chung/E&E News/POLITICO via AP Images)

Sen­ate Fi­nance chair con­tin­ues his in­ves­ti­ga­tion in­to phar­ma tax­es with re­quests for Am­gen

Am­gen is the lat­est phar­ma com­pa­ny to ap­pear on the radar of Sen­ate Fi­nance Com­mit­tee Chair Ron Wyden (D-OR), who is in­ves­ti­gat­ing the way phar­ma com­pa­nies are us­ing sub­sidiaries in low- or ze­ro-tax coun­tries to low­er their tax bills.

Like its peers Mer­ck, Ab­b­Vie and Bris­tol My­ers Squibb, Wyden notes how Am­gen us­es its Puer­to Ri­co op­er­a­tions to con­sis­tent­ly pay tax rates that are sub­stan­tial­ly low­er than the U.S. cor­po­rate tax rate of 21%, with an ef­fec­tive tax rate of 10.7% in 2020 and 12.1% in 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.